CN101036651A - 盐酸纳络酮口腔及鼻腔喷雾剂 - Google Patents
盐酸纳络酮口腔及鼻腔喷雾剂 Download PDFInfo
- Publication number
- CN101036651A CN101036651A CN 200610013316 CN200610013316A CN101036651A CN 101036651 A CN101036651 A CN 101036651A CN 200610013316 CN200610013316 CN 200610013316 CN 200610013316 A CN200610013316 A CN 200610013316A CN 101036651 A CN101036651 A CN 101036651A
- Authority
- CN
- China
- Prior art keywords
- naloxone hydrochloride
- acid
- oral cavity
- nasal mist
- naloxone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RGPDIGOSVORSAK-STHHAXOLSA-N naloxone hydrochloride Chemical compound Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C RGPDIGOSVORSAK-STHHAXOLSA-N 0.000 title claims abstract description 41
- 229960005250 naloxone hydrochloride Drugs 0.000 title claims abstract description 39
- 238000005507 spraying Methods 0.000 title abstract 4
- 210000000214 mouth Anatomy 0.000 claims abstract description 22
- 238000010521 absorption reaction Methods 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 239000003513 alkali Substances 0.000 claims abstract description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 239000007922 nasal spray Substances 0.000 claims description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 150000002576 ketones Chemical class 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- -1 polyoxyethylene Polymers 0.000 claims description 6
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 4
- OCTANWXFBPBMPD-UHFFFAOYSA-N CCCCCCCCCCCC[N] Chemical compound CCCCCCCCCCCC[N] OCTANWXFBPBMPD-UHFFFAOYSA-N 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- 230000002421 anti-septic effect Effects 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 4
- 229940099352 cholate Drugs 0.000 claims description 4
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 4
- 229940009976 deoxycholate Drugs 0.000 claims description 4
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 4
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 claims description 4
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 4
- 230000003204 osmotic effect Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 235000010199 sorbic acid Nutrition 0.000 claims description 4
- 239000004334 sorbic acid Substances 0.000 claims description 4
- 229940075582 sorbic acid Drugs 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000002562 thickening agent Substances 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 3
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- CJPDBKNETSCHCH-UHFFFAOYSA-N 1-methylsulfinyldodecane Chemical compound CCCCCCCCCCCCS(C)=O CJPDBKNETSCHCH-UHFFFAOYSA-N 0.000 claims description 2
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- 108010007979 Glycocholic Acid Proteins 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 239000005639 Lauric acid Substances 0.000 claims description 2
- 235000017858 Laurus nobilis Nutrition 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 2
- 235000021360 Myristic acid Nutrition 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 2
- 235000005212 Terminalia tomentosa Nutrition 0.000 claims description 2
- 244000125380 Terminalia tomentosa Species 0.000 claims description 2
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229960002152 chlorhexidine acetate Drugs 0.000 claims description 2
- 229960004926 chlorobutanol Drugs 0.000 claims description 2
- 229960004106 citric acid Drugs 0.000 claims description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 claims description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims description 2
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims description 2
- 229940116333 ethyl lactate Drugs 0.000 claims description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229940070765 laurate Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 229940055577 oleyl alcohol Drugs 0.000 claims description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 claims description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 235000011067 sorbitan monolaureate Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 claims description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 2
- 229940033663 thimerosal Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 210000002200 mouth mucosa Anatomy 0.000 abstract 2
- 229960004127 naloxone Drugs 0.000 abstract 2
- 210000003928 nasal cavity Anatomy 0.000 abstract 2
- 210000002850 nasal mucosa Anatomy 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 208000010513 Stupor Diseases 0.000 description 3
- 238000001467 acupuncture Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZLWULWWXACZTPR-UHFFFAOYSA-N [ClH]=O Chemical compound [ClH]=O ZLWULWWXACZTPR-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种盐酸纳络酮口腔及鼻腔喷雾剂。其由作为活性成分的盐酸纳络酮、纳络酮游离碱或医药上可接受的纳络酮的其它药用盐与药用辅料以1∶2.5~10的重量比按照常规的喷雾剂制备工艺制成。本发明提供的盐酸纳络酮口腔及鼻腔喷雾剂中的有效成分可通过患者口腔或鼻腔粘膜下的毛细管吸收后直接进入体内循环,因而起效快且生物利用度高,而且对口腔或鼻腔粘膜无刺激。特别是本发明的药物不受使用场合的限制,因而使用方便,而且给药剂量可控及毒副作用小。
Description
技术领域
本发明属于医药领域,特别是涉及一种盐酸纳络酮口腔及鼻腔喷雾剂。
背景技术
盐酸纳络酮的化学名称为17-烯丙基-4,5α-环氧基-3,14-二羟基吗啡喃-6酮盐酸盐无水合物、单水合物或二水合物。其为一种阿片受体拮抗剂,本身无内在活性,但能竞争性拮抗各类阿片受体,对μ受体具有很强的亲和力,具有生效迅速及拮抗作用强等特点,临床上主要用于治疗因服用麻醉性镇痛药过量而导致的呼吸抑制及昏迷等症状,从而引起患者高度兴奋,以使其心血管功能亢进。目前临床上使用的盐酸纳络酮制剂均为经过皮下、肌肉或静脉注射途径给药的水针制剂和粉针制剂。虽然这些盐酸纳络酮制剂具有起效快、生物利用度高且易于剂量调整和控制等优点,但由于盐酸纳络酮的分子结构中含有酚羟基结构,因而化学性质不稳定,所以在将其制备成水针制剂的过程中有可能因加热灭菌而造成药物分解。尽管粉针制剂可以避免该药物因高温受热而引起的分解变质,且贮存期相对较长,但其与水针制剂一样都需要由经过专业训练的医护人员给患者进行注射,因而使用的场合受到极大的限制。
发明内容
为了解决上述问题,本发明的目的在于提供一种给药方便、吸收及起效快、对口腔及鼻腔粘膜无刺激且生物利用度高的盐酸纳络酮口腔及鼻腔喷雾剂。
为了达到上述目的,本发明提供的盐酸纳络酮口腔及鼻腔喷雾剂由作为活性成分的盐酸纳络酮、纳络酮游离碱或医药上可接受的纳络酮的其它药用盐与药用辅料以1∶2.5~10的重量比按照常规的喷雾剂制备工艺制成。
所述的药用辅料包括吸收促进剂、渗透压调节剂、增稠剂、防腐剂和表面活性剂。
所述的吸收促进剂选自甲基-β-环糊精、二甲基-β-环糊精、羟丙基-β-环糊精、甘胆酸盐、胆酸盐、去氧胆酸盐、牛黄胆酸盐、葡萄糖胆酸盐、鹅去氧胆酸盐、乌索去氧胆酸盐、月桂酸、油酸、肉豆蔻酸、癸酸、月桂酸酯、辛酯酸、葵酸酯、棕榈酸酯、乳酸乙酯、丙二醇、异丙醇、十六醇、月桂醇、油醇、聚氧乙烯月桂醚、聚氧乙烯辛醚、十二烷基甲基亚砜、二甲基亚砜、十二烷基氮卓酮、拢牛儿基氮卓酮中的任一种。
所述的渗透压调节剂选自氯化钠、乳糖、葡萄糖、右旋糖苷、山梨醇、甘露醇或其药学上可接受的无机盐。
所述的增稠剂选自羧甲基纤维素、羟丙基纤维素、聚乙二醇、聚丙烯酸、聚乙烯酸、聚乙烯吡咯烷酮、卡波普。
所述的防腐剂选自尼泊金乙酯、对羟基苯甲酸酯、苯甲酸及其药学上可接受的盐、山梨酸、枸橼酸、三氯叔丁醇、苯甲醇、硫柳汞、醋酸洗必泰及季铵化合物。
所述的表面活性剂选自十二烷基硫酸钠、辛酸单甘油酯、吐温80、司盘20或它们的混合物。
本发明提供的盐酸纳络酮口腔及鼻腔喷雾剂中的有效成分可通过患者口腔或鼻腔粘膜下的毛细管吸收后直接进入体内循环,因而起效快且生物利用度高,而且对口腔或鼻腔粘膜无刺激。特别是本发明的药物不受使用场合的限制,因而使用方便,而且给药剂量可控及毒副作用小。
具体实施方式
下面结合具体实施例详细说明本发明提供的盐酸纳络酮口腔及鼻腔喷雾剂。
实施例1:盐酸纳络酮喷雾剂
处方:
盐酸纳络酮 0.4g
聚乙烯吡咯烷酮 0.6g
拢牛儿基氮卓酮 5ml
辛酸单甘油酯 0.05g
枸橼酸 0.3g
尼泊金乙酯 0.1g
注射用水 稀释至1000ml
制法:将上述处方量的盐酸纳络酮、聚乙烯吡咯烷酮、拢牛儿基氮卓酮、辛酸单甘油酯、枸橼酸、尼泊金乙酯充分混匀并使全部溶解,最后补加注射用水至全量,制成澄清的溶液。抽样检验合格后将所得溶液分装于喷雾泵或定量滴泵中。
实施例2:盐酸纳络酮喷雾剂
处方:
盐酸纳络酮 0.4g
羟丙基-β-环糊精 0.8g
十二烷基氮卓酮 3ml
聚乙二醇4000 1.0g
吐温80 1.0g
山梨酸 0.1g
注射用水 稀释至1000ml
制法:将上述处方量的盐酸纳络酮、羟丙基-β-环糊精、十二烷基氮卓酮、聚乙二醇4000、吐温80、山梨酸充分混匀并使全部溶解,最后补加注射用水至全量,制成澄清的溶液。抽样检验合格后将所得溶液分装于喷雾泵或定量滴泵中。
实施例3:盐酸纳络酮喷雾剂
处方:
盐酸纳络酮 0.4g
羧甲基纤维素 1.0g
枸橼酸 0.3g
注射用水 稀释至1000ml
制法:将上述处方量的盐酸纳络酮、羧甲基纤维素、枸橼酸充分混匀并使全部溶解,最后补加注射用水至全量,制成澄清的溶液。抽样检验合格后将所得溶液分装于喷雾泵或定量滴泵中。
本发明提供的盐酸纳络酮口腔及鼻腔喷雾剂呈无色或类白色透明液体,每次用药剂量在1~4ml的范围内。
为验证本发明提供的盐酸纳络酮口腔及鼻腔喷雾剂的药效,本发明人以兔作为试验动物进行了鼻腔吸收试验:将兔放入兔盒里,用喷雾器以60°插入兔鼻内约12mm,每个鼻孔给药约30~50μl,取仰卧位约1min,从耳缘静脉采血;测定血药浓度,评价盐酸纳络酮喷雾剂的鼻腔吸收情况。结果表明盐酸纳络酮口腔及鼻腔喷雾剂的相对生物平均利用度大于98%。
另外对治疗呼吸抑制及昏迷等症状进行了临床验证。本试验中入组病例为20例,每日3次,每次1ml(相当于盐酸纳络酮0.4mg),其疗效评价的统计结果为:本发明提供的盐酸纳络酮口腔及鼻腔喷雾剂的愈显率为96.7%,同时没有发现任何不良反应。
Claims (7)
1、一种盐酸纳络酮口腔及鼻腔喷雾剂,其特征在于:所述的盐酸纳络酮喷雾剂由作为活性成分的盐酸纳络酮、纳络酮游离碱或医药上可接受的纳络酮的其它药用盐与药用辅料以1∶2.5~10的重量比按照常规的喷雾剂制备工艺制成。
2、根据权利要求1所述的盐酸纳络酮口腔及鼻腔喷雾剂,其特征在于:所述的药用辅料包括吸收促进剂、渗透压调节剂、增稠剂、防腐剂和表面活性剂等。
3、根据权利要求2所述的盐酸纳络酮口腔及鼻腔喷雾剂,其特征在于:所述的吸收促进剂选自甲基-β-环糊精、二甲基-β-环糊精、羟丙基-β-环糊精、甘胆酸盐、胆酸盐、去氧胆酸盐、牛黄胆酸盐、葡萄糖胆酸盐、鹅去氧胆酸盐、乌索去氧胆酸盐、月桂酸、油酸、肉豆蔻酸、癸酸、月桂酸酯、辛酯酸、葵酸酯、棕榈酸酯、乳酸乙酯、丙二醇、异丙醇、十六醇、月桂醇、油醇、聚氧乙烯月桂醚、聚氧乙烯辛醚、十二烷基甲基亚砜、二甲基亚砜、十二烷基氮卓酮、拢牛儿基氮卓酮中的任一种。
4、根据权利要求2所述的盐酸纳络酮口腔及鼻腔喷雾剂,其特征在于:所述的渗透压调节剂选自氯化钠、乳糖、葡萄糖、右旋糖苷、山梨醇、甘露醇或其药学上可接受的无机盐。
5、根据权利要求2所述的盐酸纳络酮口腔及鼻腔喷雾剂,其特征在于:所述的增稠剂选自羧甲基纤维素、羟丙基纤维素、聚乙二醇、聚丙烯酸、聚乙烯酸、聚乙烯吡咯烷酮、卡波普。
6、根据权利要求2所述的盐酸纳络酮口腔及鼻腔喷雾剂,其特征在于:所述的防腐剂选自尼泊金乙酯、对羟基苯甲酸酯、苯甲酸及其药学上可接受的盐、山梨酸、枸橼酸、三氯叔丁醇、苯甲醇、硫柳汞、醋酸洗必泰及季铵化合物。
7、根据权利要求2所述的盐酸纳络酮口腔及鼻腔喷雾剂,其特征在于:所述的表面活性剂选自十二烷基硫酸钠、辛酸单甘油酯、吐温80、司盘20或它们的混合物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610013316 CN101036651A (zh) | 2006-03-16 | 2006-03-16 | 盐酸纳络酮口腔及鼻腔喷雾剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610013316 CN101036651A (zh) | 2006-03-16 | 2006-03-16 | 盐酸纳络酮口腔及鼻腔喷雾剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101036651A true CN101036651A (zh) | 2007-09-19 |
Family
ID=38887957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610013316 Pending CN101036651A (zh) | 2006-03-16 | 2006-03-16 | 盐酸纳络酮口腔及鼻腔喷雾剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101036651A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015095644A1 (en) * | 2013-12-20 | 2015-06-25 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| RU2572217C2 (ru) * | 2013-10-21 | 2015-12-27 | Российская Федерация, от имени которой выступает Федеральное государственное казенное учреждение "Войсковая часть 68240" | Фармацевтическая композиция в виде назального спрея на основе налоксона гидрохлорида и способ ее получения |
| JP2017519803A (ja) * | 2014-07-08 | 2017-07-20 | インシス・ファーマ・インコーポレーテッド | 舌下ナロキソンスプレー |
| US20230181500A1 (en) * | 2020-05-04 | 2023-06-15 | Amphastar Pharmaceuticals, Inc. | Naloxone Pharmaceutical Formulations for Intranasal (IN) Delivery |
-
2006
- 2006-03-16 CN CN 200610013316 patent/CN101036651A/zh active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2572217C2 (ru) * | 2013-10-21 | 2015-12-27 | Российская Федерация, от имени которой выступает Федеральное государственное казенное учреждение "Войсковая часть 68240" | Фармацевтическая композиция в виде назального спрея на основе налоксона гидрохлорида и способ ее получения |
| WO2015095644A1 (en) * | 2013-12-20 | 2015-06-25 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| US9192570B2 (en) | 2013-12-20 | 2015-11-24 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| US9289425B2 (en) | 2013-12-20 | 2016-03-22 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| JP2017519803A (ja) * | 2014-07-08 | 2017-07-20 | インシス・ファーマ・インコーポレーテッド | 舌下ナロキソンスプレー |
| EP3177146A4 (en) * | 2014-07-08 | 2018-01-03 | Insys Pharma, Inc. | Sublingual naloxone spray |
| US20230181500A1 (en) * | 2020-05-04 | 2023-06-15 | Amphastar Pharmaceuticals, Inc. | Naloxone Pharmaceutical Formulations for Intranasal (IN) Delivery |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2572692C2 (ru) | Сублингвальные композиции дексмедетомидина и способы их применения | |
| US11116750B2 (en) | Ready to use ketorolac formulations | |
| US20070209660A1 (en) | Intranasal Opioid Compositions, Delivery Devices and Methods of Using Same | |
| EP4000601A1 (en) | Stable ast-3424 injection preparation and preparation method | |
| AU2004268602A2 (en) | Intranasal opioid compositions | |
| US20170079907A1 (en) | Sublingual Epinephrine Spray | |
| WO2020259440A1 (zh) | 右美托咪定鼻喷剂、其制备方法及应用 | |
| US20240216360A1 (en) | Drug products for intranasal administration and uses thereof | |
| CN112386565B (zh) | 一种马钱子碱凝胶制剂及其制备方法 | |
| US11786461B2 (en) | Naloxone formulations for sublingual and/or buccal administration | |
| CN101036651A (zh) | 盐酸纳络酮口腔及鼻腔喷雾剂 | |
| CN111825548A (zh) | 一种含有芳基丙酸类化合物的药物组合物 | |
| KR20110017433A (ko) | 비강내 투여용 케토로락의 약학적 제형물 | |
| CN1305474C (zh) | 盐酸纳美芬鼻腔给药制剂 | |
| CN1726915B (zh) | 盐酸纳洛酮鼻腔给药系统或组合物及其制备方法 | |
| CN101036650A (zh) | 盐酸纳络酮滴丸 | |
| US20130274650A1 (en) | Stabilized ketorolac compositions | |
| WO2022038403A1 (ru) | Фармацевтическая композиция на основе налбуфина и/или его солей для назального применения | |
| WO2010094218A1 (zh) | 一种含帕洛诺司琼的口腔喷雾剂或气雾剂 | |
| CN1498613A (zh) | 5-ht3受体拮抗剂鼻粘膜喷雾给药组合物及其用途 | |
| CN102847161A (zh) | 四氢嘧啶及其衍生物在制备药物肺部收促进剂中的应用 | |
| HK40026993B (zh) | 即用型酮咯酸配方 | |
| HK40045120A (zh) | 一种马钱子碱凝胶制剂及其制备方法 | |
| HK40026993A (zh) | 即用型酮咯酸配方 | |
| HK40067950A (zh) | 药物合成物输送器械和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |